Clinical Trial Update: Hypercoagulability and Thromboembolic Risk in Patients With Malignant Disease, Evaluated by Thrombelastograph (TEG®)

View source ↗

Summary

An ongoing clinical trial evaluating hypercoagulability and thromboembolic risk in patients with malignant disease using thrombelastography (TEG).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Snippet

Sponsor: Rigshospitalet, Denmark | Conditions: Cancer | Status: UNKNOWN